ライフサイエンスコーパス: thrombomodulin

1 selectin, intracellular adhesion molecule-1, thrombomodulin).

2 antitrypsin) and endothelial injury (soluble thrombomodulin).

3 y receptors (endothelial protein C receptor, thrombomodulin).

4 es 1700-fold in the presence of the cofactor thrombomodulin.

5 KLF2, endothelial nitric oxide synthase, and thrombomodulin.

6 factor for aHUS in the form of mutations in thrombomodulin.

7 pression of the endothelial KLF2 target gene thrombomodulin.

8 bin was enhanced 60-80-fold independently of thrombomodulin.

9 e anticoagulant protein C in the presence of thrombomodulin.

10 C in the absence or presence of the cofactor thrombomodulin.

11 posttranslational, O-linked glycosylation of thrombomodulin.

12 itope changes drastically in the presence of thrombomodulin.

13 in in a reaction accelerated by the cofactor thrombomodulin.

14 C-terminal subdomain of EGF-like module 5 of thrombomodulin.

15 n the EPCR concentration is in excess of the thrombomodulin.

16 ntithrombin complex, IL-6, IL-8, and soluble thrombomodulin.

17 rotein C with the assistance of the cofactor thrombomodulin.

18 inal subdomain of EGF-like module 5 of human thrombomodulin.

19 ets include tissue plasminogen activator and thrombomodulin.

20 n by plasmin but not by thrombin or thrombin:thrombomodulin.

21 ipts included matrix metalloproteinase-1 and thrombomodulin.

22 oietin-2, von Willebrand Factor, and soluble thrombomodulin.

23 reaction greatly accelerated by the cofactor thrombomodulin.

24 um von Willebrand factor and decreased serum thrombomodulin.

25 face expression of endothelial anticoagulant thrombomodulin.

26 e and mice lacking the lectin-like domain of thrombomodulin.

27 tion was measured in the presence of soluble thrombomodulin.

28 ndothelial nitric oxide synthase (eNOS), and thrombomodulin.

29 d and treated with recombinant human soluble thrombomodulin (0.06 mg/kg/d; n = 395) or equivalent pla

30 05 (247-346) vs. 256 (224-294) p = 0.002 and thrombomodulin (7.1 [5.5-8.1] vs. 3.57 [3.03-4.71] p < 0

31 Anti-VCAM/LNP-mRNA mediated expression of thrombomodulin (a natural endothelial inhibitor of throm

32 We investigated changes in the expression of thrombomodulin, a key component of the anticoagulant pro

33 Thrombomodulin, a transmembrane glycoprotein, exerts ant

34 e ability of mevastatin to increase eNOS and thrombomodulin accumulation in endothelial cells.

35 We propose that the mechanism of thrombomodulin action is to kinetically facilitate the p

36 ood hemostasis parameters, including soluble thrombomodulin, activated protein C, and disseminated in

37 issue factor (TF), and the importance of the thrombomodulin-activated protein C inhibitory pathway.

38 Furthermore, activation of the thrombomodulin-activated protein C pathway in the region

39 In an in vivo thrombin-infusion model of thrombomodulin activation in cynomolgus monkeys, previou

40 on is present and that natural anticoagulant/thrombomodulin activity is important after transplant.

41 An adenoviral construct expressing thrombomodulin (Adv/RSV-THM) was created and functionall

42 Thrombomodulin also accelerates the proteolytic activati

43 site providing a potential mechanism of how thrombomodulin alters thrombin substrate specificity.

44 is dependent on the complex of thrombin and thrombomodulin, an integral endothelial surface receptor

45 tors required for both protein C activation (thrombomodulin and EPCR) and APC cellular signaling (EPC

46 and hemorrhage were associated with elevated thrombomodulin and ferritin levels.

47 Soluble thrombomodulin and its parent molecule appear to play a

48 High thrombomodulin and low protein C levels were significant

49 creasing BD was associated with high soluble thrombomodulin and low protein C levels.

50 that PF4 binds to GAG+ but not GAG- forms of thrombomodulin and native but not Gla-domainless protein

51 ), 2 were inconsistent with earlier reports (thrombomodulin and plasminogen activator inhibitor 1), a

52 transition requires the combined binding of thrombomodulin and protein C and restores activity of th

53 electively shifted to the active E form upon thrombomodulin and protein C binding.

54 Admission plasma thrombomodulin and protein C levels are predictive of cl

55 ch families, and the anticoagulant proteins, thrombomodulin and protein C.

56 is a significant interaction between soluble thrombomodulin and soluble intercellular adhesion molecu

57 Combinatorial analysis of soluble thrombomodulin and soluble intercellular adhesion molecu

58 he activated ECs and on the concentration of thrombomodulin and the degree of heparan-sulfate acceler

59 It is evident that thrombomodulin and the endothelial cell protein C recept

60 This study examined whether thrombomodulin and the endothelial cell protein C recept

61 n C in a reaction that requires the cofactor thrombomodulin and the endothelial protein C receptor.

62 inverse relationship between plasma soluble thrombomodulin and the relative risk of coronary heart d

63 Concentrations of thrombomodulin and tissue factor were quantified by West

64 fold faster than wild-type in the absence of thrombomodulin and, over a slower time scale, spontaneou

65 n molecule, vascular cell adhesion molecule, thrombomodulin) and inflammatory biomarkers (C-reactive

66 ociated with amplification of E-selectin and thrombomodulin, and a reduction in protein C.

67 immunoreactivity for von Willebrand factor, thrombomodulin, and angiotensin-converting enzyme were c

68 ment 1.2 (PF1.2) and p-selectin, fibrinogen, thrombomodulin, and d-dimer.

69 uced levels of Kruppel-like factors 2 and 4, thrombomodulin, and eNOS mRNA, suggesting endothelial ce

70 HFD-fed mice had increased circulating thrombomodulin, and inhibiting thrombomodulin or thrombi

71 anscription targets nitric oxide synthase 3, thrombomodulin, and monocyte chemoattractant protein-1.

72 s reflecting endothelial damage (syndecan-1, thrombomodulin, and sE-selectin) were measured and demog

73 ed interleukin-1alpha (IL-1alpha), IL-8, and thrombomodulin, and the protein expression of these gene

74 protein 1 (MMP-1), MMP-3, MMP-9, P-selectin, thrombomodulin, and vascular endothelial growth factor w

75 nine residues, including apolipoprotein A-I, thrombomodulin, and von Willebrand factor, may contribut

76 inhibitor (TAFI) normalized PG, revealing a thrombomodulin- and TAFI-dependent antifibrinolytic mech

77 atory proteins (CD55, CD59, CD46, and CD141 [thrombomodulin]) and AP components in human glomerular m

78 was selectively impaired by 35% (P<0.05) and thrombomodulin anticoagulant activity was decreased by 2

79 Individuals with a high level of soluble thrombomodulin are associated with a significant reducti

80 tein where thrombin and the EGF456 domain of thrombomodulin are connected through a peptide linker.

81 both endothelial cell protein C receptor and thrombomodulin are down-regulated in coronary arteries w

82 ated activation of protein C by MzT bound to thrombomodulin are regulated by Na+-induced allosteric t

83 e are strongly coupled in the recognition of thrombomodulin, as seen for the interaction of human gro

84 Thrombomodulin-associated coagulopathy (TM-AC) is a newl

85 ulated endothelial nitric oxide synthase and thrombomodulin at mRNA and protein levels.

86 The epitope for thrombomodulin binding is shaped as a hot spot in exosit

87 smaller subset of the structural epitope for thrombomodulin binding recently documented by x-ray crys

88 e and proteinase-like, is affected by Na(+), thrombomodulin binding, or active site ligation.

89 changes occur in the active site loops upon thrombomodulin binding.

90 found unexpectedly to significantly increase thrombomodulin binding.

91 ad decreased expression of endothelium-bound thrombomodulin, but extremely elevated levels of soluble

92 Preincubation of thrombin with soluble thrombomodulin, but not heparin, inhibited the proteolys

93 ereas the K(m) for the thrombin- or thrombin:thrombomodulin-catalyzed reaction is 10-40-fold higher t

94 Thrombomodulin colocalization with these receptors on th

95 ugments protein C activation by the thrombin-thrombomodulin complex about 5-fold in vitro.

96 Although the thrombin/thrombomodulin complex activated all the mutants, carbox

97 menting protein C activation by the thrombin-thrombomodulin complex and in modulating the functions o

98 ein C to activated protein C by the thrombin.thrombomodulin complex by increasing its affinity for pr

99 adict amide exchange studies on the thrombin-thrombomodulin complex that suggested subtle changes occ

100 protein C likely interacts with the thrombin-thrombomodulin complex through a rigid body association

101 hibited protein C activation by the thrombin/thrombomodulin complex, it still increased the sensitivi

102 B (CPB), which is activated by the thrombin/thrombomodulin complex, plays a procoagulant role during

103 al and structural properties of the thrombin-thrombomodulin complex, prolongs the clotting time by ge

104 ugments protein C activation by the thrombin-thrombomodulin complex.

105 bin in the crystal structure of the thrombin-thrombomodulin complex.

106 ation of wild-type protein C by the thrombin-thrombomodulin complex.

107 surface area upon formation of the thrombin-thrombomodulin complex.

108 the activation of protein C by the thrombin-thrombomodulin complex.

109 n C and enhancing activation by the thrombin-thrombomodulin complex.

110 menting protein C activation by the thrombin-thrombomodulin complex.

111 cement in protein activation by the thrombin-thrombomodulin complex.

112 litates protein C activation by the thrombin-thrombomodulin complex.

113 , and nifedipine) abolished the reduction in thrombomodulin concentration observed after arterial flo

114 Thrombomodulin concentrations after 90 minutes of venous

115 In all patients, soluble thrombomodulin concentrations greater than 3.26 ng/mL we

116 Thrombomodulin concentrations were determined by an enzy

117 A thrombomodulin construct lacking EGF-like domain 3 funct

118 Thrombomodulin controls the complement arm of the innate

119 d more quickly and von Willebrand factor and thrombomodulin decreased more slowly in those with compl

120 We show that the abortion of thrombomodulin-deficient embryos is caused by tissue fac

121 Two mouse models (thrombomodulin-deficient TMPro mice and factor V Leiden

122 n 293 cells that coexpress EPCR variants and thrombomodulin demonstrate that protein C binding to EPC

123 VEGF-induced, thrombomodulin-dependent activation of protein C was dep

124 amily of molecules, accelerates the thrombin-thrombomodulin-dependent generation of activated protein

125 D), implying endothelial hypofunctioning for thrombomodulin-dependent generation of activated protein

126 ve than thrombin or meizothrombin(desF1) for thrombomodulin-dependent protein C activation.

127 Recombinant human soluble thrombomodulin did not significantly reduce 28-day all-c

128 work (factor IIa, factor V, factor VIII, and thrombomodulin), did not affect the existence of this re

129 oups, mice lacking the lectin-like domain of thrombomodulin displayed strongly attenuated systemic in

130 have used recombinant lectin-like domain of thrombomodulin domain 1 (TMD1) to demonstrate the action

131 r-beta antibody, which effectively prevented thrombomodulin downregulation during acute pressure over

132 In vitro co-culture studies revealed that thrombomodulin downregulation is caused by the paracrine

133 n molecule, vascular cell adhesion molecule, thrombomodulin, endocan, C-reactive protein, interleukin

134 wth factor, vascular cell adhesion molecule, thrombomodulin, endocan, interleukin-6, and interleukin-

135 For example, porcine thrombomodulin expressed on porcine aortic endothelial c

136 aused a 70% inhibition of atrial endocardial thrombomodulin expression and resulted in increased loca

137 However, thrombomodulin expression decreases in perturbed endothe

138 Decreased thrombomodulin expression may cause defective function o

139 Targeted restoration of atrial thrombomodulin expression with adenovirus-mediated gene

140 mice lacking the blood coagulation regulator thrombomodulin, fibrinolytic degradation products (FDP)

141 active site does not change the affinity of thrombomodulin fragments binding to exosite 1; however,

142 estigation demonstrated that ablation of the thrombomodulin gene in mice causes embryonic lethality b

143 nt intima-to-media ratio was observed in the thrombomodulin group relative to controls.

144 y increases in the recombinant human soluble thrombomodulin group were lower or negligible with incre

145 complement regulatory protein CD46 and human thrombomodulin (GTKO.hCD46.hTBM), that were transplanted

146 The lectin-like domain of thrombomodulin has anti-inflammatory properties.

147 tive fragment of its anticoagulant cofactor, thrombomodulin, have been determined by surface plasmon

148 ients treated with recombinant human soluble thrombomodulin having higher baseline thrombin generatio

149 spect to known interactions of thrombin with thrombomodulin, hirudin, rhodniin and heparin cofactor I

150 Transgenic expression of human thrombomodulin (hTBM), which has the potential to solve

151 ion of PAEC with the gene encoding for human thrombomodulin (hTM) resulted in expression of high leve

152 ion of activated protein C (aPC) by thrombin/thrombomodulin (IIa/TM) in the presence of PF4.

153 giopoietin-2, von Willebrand factor, soluble thrombomodulin), impaired oxygenation (Pa(O(2))/Fi(O(2))

154 clusion of the endothelial markers ICAM1 and thrombomodulin in a logistic regression model resulted i

155 thrombin (within exosite I) also employed by thrombomodulin in its cofactor-enhanced activation of pr

156 in, but extremely elevated levels of soluble thrombomodulin in plasma, impairing the propagation phas

157 nd decreased protein C activation because of thrombomodulin inactivation.

158 , the anti-inflammatory/anti-coagulant CD141/thrombomodulin increased markedly when IL-32 was silence

159 ion as a function of temperature reveal that thrombomodulin increases >1,000-fold the rate of diffusi

160 In competition experiments, thrombomodulin inhibited fibrin-enhanced factor XIII act

161 vironment around the scissile bond for II(a)/thrombomodulin interaction.

162 Endothelial thrombomodulin is a major vasoprotective molecule.

163 Thrombomodulin is a multidomain receptor primarily expre

164 Thrombomodulin is a necessary factor in the anticoagulan

165 The membrane thrombomodulin is digested by proteases and the degradat

166 ession of endothelial NO synthase (eNOS) and thrombomodulin is KLF2 dependent.

167 or the first time a detrimental role for the thrombomodulin lectin-like domain in the host response t

168 this study, we investigated the role of the thrombomodulin lectin-like domain in the host response t

169 Individuals with a high soluble thrombomodulin level do not have an increased risk of co

170 The soluble thrombomodulin level in plasma is an independent risk fa

171 mug/mL; 95% CI, -8.2 to 24.11; P = .33) and thrombomodulin levels (14.5 vs 13.8 ng/mL; difference, 0

172 Posttransplant thrombomodulin levels are elevated after transplant but

173 eactive protein levels) and vascular injury (thrombomodulin levels) measured at 0, 48, 96, and 168 ho

174 In contrast, at low soluble thrombomodulin levels, soluble intercellular adhesion mo

175 P<0.0001) but not of d-dimer, fibrinogen, or thrombomodulin levels.

176 t F1+2 and d-dimer), and endothelial damage (thrombomodulin) markers to near-normal levels.

177 Homozygous thrombomodulin-mutant ThbdPro mice, which have elevated

178 The same thrombomodulin mutation has been recently described in a

179 ity and thrombin generation in the demise of thrombomodulin-null embryos, and suggests that platelets

180 93 and CD248 directly bind to MMRN2 and only thrombomodulin of the family does not.

181 The impact of local overexpression of thrombomodulin on in vivo thrombus formation was subsequ

182 is inhibitor (TAFI) is activated by thrombin/thrombomodulin on the endothelial cell surface, and func

183 fect of Ca(2+) and the stimulatory effect of thrombomodulin on the rate of zymogen activation.

184 in the absence or presence of tissue factor, thrombomodulin or activated protein C.

185 Recombinant thrombomodulin or APC administration decreases acute GVH

186 PF4 had no measurable interaction with GAG- thrombomodulin or Gla-domainless protein C.

187 d circulating thrombomodulin, and inhibiting thrombomodulin or thrombin-activatable fibrinolysis inhi

188 Soluble thrombomodulin plasma concentrations are elevated in ste

189 -Endothelial thrombomodulin plays a critical role in hemostasis by bi

190 ative feedback of the protein C pathway with thrombomodulin produced nonstationary patterns of wave f

191 endothelial cells, the increase in KLF2 and thrombomodulin protein by shRNA-induced decrease in p66s

192 of endothelial protein C receptor (EPCR) and thrombomodulin protein expressions, inhibited tissue tum

193 imes, prothrombin fragments 1+2, fibrinogen, thrombomodulin, protein C, plasminogen activator inhibit

194 Alterations in the thrombomodulin-protein C pathway are consistent with act

195 These findings show a new function for the thrombomodulin-protein C system in controlling the growt

196 03 regarding cationic proteins, PF4, and the thrombomodulin-protein C system was reviewed.

197 -kappaB activation and the impairment of the thrombomodulin-protein C-EPCR anticoagulation pathway.

198 local, suppressive role of the anticoagulant thrombomodulin/protein C pathway under flow.

199 VWF antigen (r = 0.38; p=0.0022) and soluble thrombomodulin (r = 0.38; p=0.0078) among all patients.

200 that statin-dependent induction of eNOS and thrombomodulin requires KLF2 and thereby provides a nove

201 Recombinant thrombomodulin (rTM) has been used for treatment of seps

202 omplement receptor 1 (sCR1), and recombinant thrombomodulin (rTM), were compared in a murine model of

203 f circulating mitochondrial (mt)DNA, soluble thrombomodulin (sCD141) and ICAM-1, reflecting endotheli

204 llei, mice lacking the lectin-like domain of thrombomodulin showed a survival advantage, accompanied

205 von Willebrand Factor (VWF) antigen, soluble thrombomodulin, soluble P-selectin, and soluble CD40 lig

206 We studied the effect of soluble thrombomodulin (sTM) in a hypoperfusion model of ischemi

207 ular adhesive molecule-1 (sICAM) and soluble thrombomodulin (sTM) levels are associated with risk of

208 ecule-1 (sVCAM-1), E-selectin (sE-Selectin), thrombomodulin (sTM), tissue factor (sTF) and vascular e

209 [eg, von Willebrand factor (vWf) and soluble thrombomodulin (sTM)]) and raised plasma levels of brain

210 conditions, there is rapid downregulation of thrombomodulin, sufficient to limit protein C activation

211 (histone-complexed DNA fragments, annexin V, thrombomodulin, syndecan-1), platelet activation (solubl

212 lower expression of ICAM1, ICAM2, VCAM1, and thrombomodulin than do HUVEC and HMVEC.

213 l malfunction associated with the absence of thrombomodulin than fibrin formation.

214 Solulin is a soluble form of thrombomodulin that is resistant to proteolysis and oxid

215 537Stop), which predicts a truncated form of thrombomodulin that is shed from the vascular endotheliu

216 some 20 (and putatively on the THBD gene for thrombomodulin) that increased the risk of venous thromb

217 Absence of the blood coagulation inhibitor thrombomodulin (Thbd) from trophoblast cells of the mous

218 gote minor allele of a common variant in the thrombomodulin (THBD) gene (rs1042579) was independently

219 ene encoding the blood coagulation inhibitor thrombomodulin (Thbd) leads to embryonic lethality cause

220 ial cell stress is involved, and endothelial thrombomodulin (THBD) plays a role in this process.

221 that SNPs on chromosome 20 are cis-eQTLs for thrombomodulin (THBD), and the expression of THBD is low

222 d high levels of the antithrombotic proteins thrombomodulin (THBD), endothelial protein C receptor (E

223 Here we identify the thrombomodulin (Thbd)-activated protein C (aPC) pathway

224 ng were also induced, including plasminogen, thrombomodulin, the urokinase-type plasminogen activator

225 Thrombomodulin thus represents a central mechanism by wh

226 Overexpression of KLF2 strongly induced thrombomodulin (TM) and endothelial nitric oxide synthas

227 n of the anticoagulant endothelial receptors thrombomodulin (TM) and endothelial protein C receptor (

228 use PECAM-1 antibodies to recombinant murine thrombomodulin (TM) and endothelial protein C receptor (

229 f the anticoagulant and protective receptors thrombomodulin (TM) and endothelial protein C receptor (

230 ned radiation-induced changes in endothelial thrombomodulin (TM) and protease-activated receptor-1 (P

231 Now we isolate human EPCR and thrombomodulin (TM) and reconstitute them into phosphati

232 he expression of the anticoagulant proteins, thrombomodulin (TM) and the endothelial cell protein C r

233 nsion leads to PDGFR activation and identify thrombomodulin (TM) as an Akt and AP-1 target in SMC.

234 ess the endothelial-specific genes tie-2 and thrombomodulin (TM) as well as the early mesodermal mark

235 Statins upregulate endothelial thrombomodulin (TM) by mechanisms that involve members o

236 Endothelial thrombomodulin (TM) changes thrombin's substrate specifi

237 en to make the fibrin clot, but the thrombin-thrombomodulin (TM) complex initiates the anticoagulant

238 ctivated protein C (APC) by soluble thrombin/thrombomodulin (TM) complexes up to 25-fold.

239 Thrombomodulin (TM) forms a 1:1 complex with thrombin.

240 Thrombomodulin (TM) functions as a cofactor to enhance t

241 Sporadic mutations in the thrombomodulin (TM) gene occur in patients with both art

242 order in which a p.Cys537Stop variant in the thrombomodulin (TM) gene THBD, results in high plasma TM

243 The thrombomodulin (TM) gene was ablated in mice in a cell t

244 is study used mice with modifications of the thrombomodulin (TM) gene, the tissue-type plasminogen ac

245 The endothelial cell surface receptor thrombomodulin (TM) inhibits blood coagulation by formin

246 Thrombomodulin (TM) is a cofactor for protein C activati

247 Thrombomodulin (TM) is a cofactor for thrombin-mediated

248 Thrombomodulin (TM) is a predominantly endothelial trans

249 The interaction of thrombin (IIa) with thrombomodulin (TM) is essential for the efficient activ

250 Thrombomodulin (TM) is expressed on the endothelial surf

251 The cofactors heparin, vitronectin (VN), and thrombomodulin (TM) modulate the reactivity of alpha-thr

252 In this study, we describe a novel thrombomodulin (TM) mutation (c.1611C>A) that codes for

253 rporating the catalytically active domain of thrombomodulin (TM) onto the micelle corona for the loca

254 Endothelial thrombomodulin (TM) regulates coagulation and inflammati

255 Thrombin undergoes allosteric modulation by thrombomodulin (TM) that results in a shift in macromole

256 The binding of thrombomodulin (TM) to exosite-1 and the binding of Na(+

257 e influence of the protein C system, soluble thrombomodulin (Tm) was also added to the reaction mixtu

258 mutants of residues in the fourth domain of thrombomodulin (TM) were prepared and assayed for protei

259 Thrombomodulin (TM), a central player of the anticoagula

260 Endothelial cell expression of thrombomodulin (TM), a key component of the anticoagulan

261 Thrombomodulin (TM), a key component of the anticoagulan

262 endothelial protective molecules, including thrombomodulin (TM), a surface receptor, and endothelial

263 Thrombomodulin (TM), a type I transmembrane glycoprotein

264 Based on evidence that abnormalities in thrombomodulin (TM), an anticoagulant endothelial glycop

265 Thrombomodulin (TM), an endothelial cell membrane recept

266 ified endothelial protein C receptor (EPCR), thrombomodulin (TM), and von Willebrand factor (VWF) by

267 RG drives transcription of the anticoagulant thrombomodulin (TM), as shown by reporter assays and chr

268 n C activation by thrombin in the absence of thrombomodulin (TM), but the metal ion is required for a

269 d that LPS binds to monocytic membrane-bound thrombomodulin (TM), but the role of monocytic TM in LPS

270 ing the fourth and fifth EGF-like domains of thrombomodulin (TM), is deleterious for TM activity.

271 Thrombomodulin (TM), or its epidermal growth factor-like

272 mediating the interactions of thrombin with thrombomodulin (TM), protein C, and thrombin-activatable

273 f intercellular adhesion molecule 1 (ICAM1), thrombomodulin (TM), tissue factor (TF) and tissue facto

274 f plasminogen activator inhibitor-1 (PAI-1), thrombomodulin (TM), tissue plasminogen activator (tPA),

275 and to deliver a prototypical surface cargo, thrombomodulin (TM), using one-to-one protein conjugates

276 s pathway is the cytokine-regulated receptor thrombomodulin (TM), which functions as a co-factor for

277 l cells (PAEC) does not provide the expected thrombomodulin (TM)-cofactor activity for human protein

278 oagulant substrates while largely preserving thrombomodulin (TM)-dependent protein C activation.

279 ovascular injury is established, the role of thrombomodulin (TM)-dependent protein C antithrombotic m

280 l other residues are poised to interact with thrombomodulin (TM).

281 dothelial cell adhesion molecule (PECAM) and thrombomodulin (TM).

282 and of the recombinant lectin-like domain of thrombomodulin (TM).

283 interface between thrombin and a fragment of thrombomodulin, TMEGF45, have been monitored by amide hy

284 Targeting thrombomodulin to circulating red blood cells augments i

285 215-217 beta-strand, and whether binding of thrombomodulin to exosite I can allosterically shift the

286 ing of a fragment of the regulatory protein, thrombomodulin, to exosite 1 on the back side of the thr

287 Human thrombomodulin transgenic PAECs are less sensitive to ac

288 ion biomarkers for recombinant human soluble thrombomodulin treatment response in sepsis-associated c

289 the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin trial: absolute risk reduction was 2.55%

290 ly, these functions do not require exogenous thrombomodulin, unlike other anticoagulant thrombin deri

291 34, endothelial cell protein C receptor, and thrombomodulin using a streptavidin-biotin-peroxidase me

292 pendent predictor of <24-hours mortality and thrombomodulin was an independent predictor of 7-day and

293 The significant reduction in thrombomodulin was attenuated if calcium was removed fro

294 e functional epitope of thrombin recognizing thrombomodulin was mapped using Ala-scanning mutagenesis

295 ator inhibitor were significantly higher and thrombomodulin was significantly lower in Fabry patients

296 ntercellular adhesion molecule 1 (ICAM1) and thrombomodulin were measured in a subgroup.

297 luding endothelial nitric-oxide synthase and thrombomodulin, whereas knockdown of Kruppellike factor

298 e but activates protein C in the presence of thrombomodulin with a specificity comparable with wild-t

299 mation regarding the relationship of soluble thrombomodulin with coronary heart disease.

300 thrombin with the endothelial cell receptor thrombomodulin with subsequent generation of activated p